Clinical Advisory Board



Prof. Andrew Scott is Director, Department of Molecular Imaging and Therapy, Austin Health; leads the Tumour Targeting Program at the Olivia Newton-John Cancer Research Institute; and Professor, University of Melbourne, La Trobe University, and Monash University. His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies, molecular imaging particularly oncology applications of PET in cancer, and as well as global advocacy of Nuclear Medicine. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies. He has published 373 peer reviewed papers and 22 book chapters, and is an inventor on 21 patents.



Dmitriy Zamarin, MD PhD is a medical oncologist and Translational Research Director in the Gynecologic Medical Oncology Service at the Memorial Sloan Kettering Cancer Center. Dr. Zamarin obtained his MD and PhD degrees from the Mount Sinai School of Medicine in New York. He completed residency in Internal Medicine at the Mount Sinai Hospital in New York and fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center, where he worked under the mentorship of Dr. James Allison and Dr. Jedd Wolchok, studying the mechanisms of response and resistance to immunomodulatory antibody therapy and oncolytic virus-based therapeutics. 

Dr. Zamarin is a principal investigator and a translational chair on several institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors. His clinical and laboratory research are focused on characterization of biomarkers in patients undergoing immunotherapy and on development of novel immunotherapeutic strategies using immunomodulatory antibodies and genetically-engineered oncolytic viruses. Specifically, by manipulating the oncolytic viruses and the immune system, Dr. Zamarin is exploring different ways to enhance the immune recognition of tumors and to develop novel treatment strategies that could overcome resistance to immune checkpoint blockade. For his work, Dr. Zamarin has received multiple awards, including Damon Runyon Foundation Fellowship Award, Ovarian Cancer Research Fund Liz Tilberis Early Career Award, and the Ovarian Cancer Academy Grant from the Department of Defense.



Dirk Jäger is Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg, Medical Director of the Medical Oncology Department at the Heidelberg University Hospital (UKHD), and is Head of the Clinical Cooperation Unit Applied Tumor-Immunity at the German Cancer Research Center (DKFZ). Dr. Jäger studied medicine at the Universities of Lübeck and Freiburg and received his MD degree in Freiburg in 1991. He specialized in the field of internal medicine and received his venia legendi at the University of Mainz in 2003. Dr. Jäger started his scientific career at Cornell Medical Center in the tumor immunology group of Yao Chen and Lloyd Old (Ludwig Institute for Cancer Research). Before he was appointed to his current positions he was head of the Tumor Immunology Laboratory of the Oncology Department, University Hospital Zurich. At NCT, Dirk Jäger is responsible for all patient care programs and counseling services. His research focuses on unmasking the full potential of the immune system to eliminate tumor cells. As part of this he specializes in development of advanced methods and drugs to characterize and manipulate tumor-host interactions, especially via modulation of the tumor environment. Dr. Jäger has shown that combinatorial immunotherapies can lead to clinical responses in otherwise non-responsive tumors. Further, his team engages in projects developing and validating cellular therapies, bispecific antibodies, and computer-based algorithms in tumor immunology. He has set up strategic alliances with several public institutions as well as with pharmaceutical industry. He is involved in over 100 clinical trials and builds on this foundation to further contribute to personalized cancer immunotherapy.



Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting, previously Defined Health. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries.  He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology.

Before joining Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds four patents in the use of ribozymes.

He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. 

Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Society of Gene and Cell Therapy (ASGCT), the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS).

Jeff is a mentor for the annual NCI/NIH Innovation Conference (NIC), a judge for the annual Informa Citeline Awards, and an advisor to Demy-Colton’s annual Biotech Showcase during JPMorgan.